培美曲塞+顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌的近期疗效及安全性观察

目的:探究培美曲塞+顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌的近期疗效及安全性。方法:收集我院肿瘤科2009年7月到2011年7月住院治疗的局部晚期非鳞癌非小细胞癌患者54例,按照随机数字表法分为研究组和对照组,每组27例,研究组给予培美曲塞+顺铂方案诱导化疗联合同期放化疗,对照组仅给予培美曲塞+顺铂方案化疗联合同期放疗,治疗2个周期,随访2年,对比两组患者的近期疗效及安全性。结果:研究组的近期有效率和控制率分别为55.56%、77.78%,高于对照组的50.33%和59.26%,有效率和控制率差异具有统计学意义(P0.05)。随访2年,研究组的中位生存期为12.77个月,1年生存率为48.15%,高于对照组中位生存期11.28个月,1年生存率40.74%,但差异无统计学意义(P0.05),研究组2年生存率为43.46%,高于对照组的25.38%,差异具有统计学意义(P0.05);研究组白细胞减少以及脱发发生率分别为37.0%、25.9%,低于对照组的81.5%和55.5%,差异具有统计学意义(均P0.05);研究组中血小板减少、血红蛋白减少、呕吐、肝功能损害、肾功能损耗、皮疹等发生率分别为40.7%、22.2%、59.2%、11.1%、7.4%、14.8%,高于对照组中各不良反应发生率分别为33.3%、18.5%、55.5%、14.8%、11.1%、7.4%,但两组间差异无统计学意义(P0.05)。结论:培美曲塞+顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌治疗效果明显,且不良反应少,可作为临床上晚期非小细胞肺癌化疗一线药物。

Clinicals Study of Short-termEfficacy and Safety of Pemetrexed Combined With Cisplatin Induction Concurrent Chemoradiotherapy in Locally Advanced Non-small-cell Lung Cancer

Objective:To study of short-term efficacy and safety of pemetrexed combined with cisplatin induction concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer.Methods:54 cases of patients with non-squamous non-small cell who treated in Oncology of our hospital from July 2009 to July 2011, were randomly divided into study group and control group, 27 cases in each group, which study group received pemetrexed and cisplatin induction combined with concurrent chernoradiotherapy, and control group were given pemetrexed and cisplatin. all patients were treating two years and following one year, compared the term effect and adverse reactions of two groups.Results:Short-term efficienecy and control rate of study group were 55.56% and 77.78%, higher than 50.33%, 59.26%of control group, the difference between the two groups having statistically significance (P<0.05).T he median survival time and survival rate of one year were 12.77 months, 48.15%, higher than 11.28 months and 40.74%, but, the difference between the two groups was no statistically significance(P>0.05), and the survival rate of two year were 43.46%, higher than 25.38%of control group, the difference between the two groups having statistically significance (P<0.05). The incidence of leukopenia deceasing and alopecia of study group were 37.0%, 25.9%, significanly lower than the 81.5%, 55.5%in control group, the diffierence of two groups having statistically significance (P<0.05). The incidence of thtombocytopenia, hemoglobin decreased, vomit, liver damage, kidney damage and rash were 40.7%, 22.2%, 59.2%, 11.1%, 7.4%, 14.8%, lower than 33.3%, 18.5%, 55.5%, 14.8%, 11.1%, 7.4%of control group, but no significant difference between the two groups(P>0.05).Conclusion:Pemetrexed combined with cisplatin induction concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer had obvious effect ,and less adverse reaction, and which can be as first-line drugs of treating non-small-cell lung cancer.